Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

Abstract

Fulvestrant was tolerated well and was at least as effective as anastrozole in the second-line treatment of patients with ABC. This new hormonaltherapy may provide a valuable treatment option for ABC in postmenopausal women.